Latest news with #TSHA
Yahoo
4 days ago
- Business
- Yahoo
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $2.785 which is equal to the closing price of Taysha's common stock on the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date. About Taysha Gene TherapiesTaysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit Company Contact:Hayleigh Collins Senior Director, Corporate Communications and Investor RelationsTaysha Gene Therapies, Media Contact:Carolyn HawleyInizio
Business Insider
6 days ago
- Business
- Business Insider
Taysha Gene Therapies announces updates from TSHA-102 clinical program
Taysha Gene Therapies (TSHA) 'announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company's analysis of the natural history study data at the 2025 International Rett Syndrome Foundation Rett Syndrome Scientific Meeting, taking place in Boston from June 9-11, 2025.' 'We are excited to present data supporting our TSHA-102 clinical program and its potential to improve function or enable achievement of developmental milestones that would significantly improve quality of life. Importantly, these findings have increased our conviction in the differentiated potential of TSHA-102 to address the high unmet needs for patients and families suffering from this devastating disease,' said Sukumar Nagendran, M.D., President and Head of Research & Development at Taysha. 'We appreciate IRSF and their ongoing partnership, as well as the individuals with Rett syndrome, their caregivers and the clinicians who contributed to the important research that has increased our understanding of the disease progression and supported our alignment with the Food and Drug Administration on a potential path to registration.'
Yahoo
6 days ago
- Business
- Yahoo
Taysha Gene Therapies, Inc. (TSHA)'s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett syndrome, following written alignment with the FDA on a single-arm, open-label pivotal trial targeting patients aged six and older. This population, shown by natural history data to have virtually zero chance of regaining developmental milestones, saw a 100% responder rate in the REVEAL Part A trial: all 10 treated patients gained or regained at least one developmental milestone post-TSHA-102, with high-dose recipients showing faster and deeper improvements. No serious adverse events or dose-limiting toxicities were reported. A scientist holding a Petri dish filled with a gene therapy sample. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)'s pivotal Part B trial, expected to launch in Q3 2025, will enroll 15 females in the developmental plateau stage, using each patient as their own control and video-based, blinded milestone assessment as the primary endpoint. The FDA's support, based on robust longitudinal data from over 1,100 Rett patients, marks a major regulatory milestone. TSHA-102, a one-time AAV9 gene therapy delivering functional MECP2, is designed to address the genetic root cause of Rett syndrome, a devastating disorder with no current disease-modifying treatments. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) will present further details at the IRSF Rett Syndrome Scientific Meeting in June. While we acknowledge the potential of TSHA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TSHA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Taysha Gene Therapies, Inc. (TSHA)'s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett syndrome, following written alignment with the FDA on a single-arm, open-label pivotal trial targeting patients aged six and older. This population, shown by natural history data to have virtually zero chance of regaining developmental milestones, saw a 100% responder rate in the REVEAL Part A trial: all 10 treated patients gained or regained at least one developmental milestone post-TSHA-102, with high-dose recipients showing faster and deeper improvements. No serious adverse events or dose-limiting toxicities were reported. A scientist holding a Petri dish filled with a gene therapy sample. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)'s pivotal Part B trial, expected to launch in Q3 2025, will enroll 15 females in the developmental plateau stage, using each patient as their own control and video-based, blinded milestone assessment as the primary endpoint. The FDA's support, based on robust longitudinal data from over 1,100 Rett patients, marks a major regulatory milestone. TSHA-102, a one-time AAV9 gene therapy delivering functional MECP2, is designed to address the genetic root cause of Rett syndrome, a devastating disorder with no current disease-modifying treatments. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) will present further details at the IRSF Rett Syndrome Scientific Meeting in June. While we acknowledge the potential of TSHA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TSHA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-02-2025
- Business
- Yahoo
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: About Taysha Gene TherapiesTaysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit Company Contact:Hayleigh Collins Director, Head of Corporate Communications and Investor RelationsTaysha Gene Therapies, Media Contact:Carolyn HawleyInizio in to access your portfolio
